Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.2 GBX | +8.51% | +10.27% | -2.86% |
Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.86% | 96.66M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+49.45% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- SCLP Stock
- News Scancell Holdings plc
- Scancell’s Skin Cancer Vaccine Trial Advances to Second Stage; Shares Up